普洛药业：甲苯磺酸多纳非尼原料药获上市批准

Core Viewpoint - Pro Pharmaceutical (000739) announced that its subsidiary, Zhejiang Pro Kangyu Pharmaceutical Co., Ltd., received the approval notice for the listing application of Tofacitinib Tosylate from the National Medical Products Administration. This innovative Class I drug is intended for the treatment of unresectable hepatocellular carcinoma and refractory differentiated thyroid cancer. The approval is expected to have a positive impact on the company's future operations [1]. Group 1 - The drug Tofacitinib Tosylate is classified as an innovative Class I drug [1]. - The drug is specifically used for treating unresectable hepatocellular carcinoma and refractory differentiated thyroid cancer [1]. - The company has signed a research and production service contract with its partner, Suzhou Zejing Biopharmaceutical Co., Ltd., with the raw material ownership belonging to Zejing [1]. Group 2 - The approval from the National Medical Products Administration is anticipated to positively influence the company's future business operations [1].